Resistance, Remission, and Qualitative Differences in HIV Chemotherapy

Emerging Infectious Diseases

Volumn 3, Issue 3, 1997, Pages 273-283

  Kirschner, Denise E ^a   Webb, G F ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANTIBIOTIC RESISTANCE; BIOLOGICAL MODEL; CD4 LYMPHOCYTE COUNT; COMPUTER SIMULATION; DRUG COMBINATION; DRUG EFFECT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; ISOLATION AND PURIFICATION; MATHEMATICS; REVIEW; TIME; VIROLOGY;

ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COMPUTER SIMULATION; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; HIV; HIV INFECTIONS; HUMANS; MATHEMATICS; MODELS, BIOLOGICAL; TIME FACTORS;

EID: 0031179658     PISSN: 10806040     EISSN: None     Source Type: Journal    
DOI: 10.3201/eid0303.970303     Document Type: Review

References (28)

1. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-6.
2. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, et al. Viral dynamics in human immuno-deficiency virus type 1 infection. Nature 1995,373:117-22.
3. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho D. HIV-1 Dynamics in vivo: clearance rate, infected cell lifespan, and viral generation time. Science 1996;271:1582-6.
4. Piatak M, Saag MS, Yang LC, Clark SJ, Kappes JC, Luk KC, et al. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 1993;259:1749-54.
5. Richman DD. HIV therapeutics. Science 1996;272:1886-7.
6. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis and therapy. Science, 1995;267:483-9.
7. Stephenson J. New anti-HIV drugs and treatment stra-tegies buoy AIDS researchers. JAMA 1996;275:579-80.
8. Carpenter CJ, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, et al. Antiretroviral therapy for HIV infection. JAMA 1996;276:146-54.
9. Collier AC, Coombs RW, Schoenfeld DA, Bassett RL, Timpone J, Baruch A, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med 1996;334:1011-7.
10. Cohen J. Shooting for the moon with drugs. Science 1996;273:302.
11. Pennisi E, Cohen J. Eradicating HIV from a patient: not just a dream? Science 1996;272:1884.
12. Grody WW, Fligiel S, Naeim F. Thymus involution in the acquired immunodeficiency syndrome. Am J Clin Pathol 1985;84:85-95.
13. Philips AN, Sabin CA, Mocroft A, Janossy G. Antiviral therapy. Nature 1995;375:195.
14. Embretson J, Zupancic M, Ribas JL, Burke RA, Racz P, Tenner-Racz K, Haase AT. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 1993;362:359-62.
15. Ho D. Viral counts in HIV infection. Science 1996;272:1124-5.
16. Mellors JW, Rinaldo CR, Gupta P, White RM, Todd JA, Kingsely LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996;272:1167-70.
17. Pantaleo G, Graziosi C, Demarest JF, Butini L, Montroni M, Fox CH, et al. HIV infection is active and progressive in lymphoid during the clinically latent stage of disease. Nature 1996;362:355-8.
18. Lafeuillade A, Poggi C, Profizi N, Tamalet C, Costes O. Human immunodeficiency virus type I kinetics in lymph nodes compared with plasma. J Infect Dis 1996;174:404-7.
19. McLean A, Nowak M. Competition between AZT sensitive and AZT resistant strains of HIV. AIDS 1992;6:71-9.
20. Fischl MA, Richmann DD, Hansen N, Collier AC, Carey JT, Para MF, et al. The safety and efficiency of AZT in the treatment of subjects with mildly symptomatic HIV type 1. Ann Intern Med 1990;112:727-37.
21. Graham NMH, Zeger SL, Park LP, Vermund SH, Detels R, Rinaldo CR, Phair JP. The effects on survival of early treatment of HIV infection. N Engl J Med 1992;326:1037-42.
22. Hamilton JD, Hartigan PM, Simberkoff MS, Day PL, Diamond GR, Dickinson GM, et al. A controlled trial of early vs late treatment with AZT in symptomatic HIV infection. N Engl J Med 1992;326:437-43.
23. Montaner JSG, Singer J, Schechter MT. Clinical correlates of in vitro HIV-1 resistance to zidovudine. Results of the Multicentre Canadian AZT trial. AIDS 1993;7:189-95.
24. Kirschner DE, Webb GF. A model for treatment strategy in the chemotherapy of AIDS. Bull Math Biol 1996;58:367-91.
25. Trough DF, Sprent J. Lifespan of lymphocytes. Immunol Res 1995;14:1-14.
26. Perelson AS, Kirschner DE, DeBoer R. The dynamics of HIV infection of CD4+ T cells. Math Biosci 1993,114:81-125.
27. Kirschner DE, Webb GF. Effects of drug resistance on monotherapy treatment of HIV infection. Bull Math Biol 1997.
28. Kirschner DE, Webb GF. A mathematical model of combined drug therapy of HIV infection. Journal of Theoretical Medicine 1997. In press.